186 related articles for article (PubMed ID: 21523391)
1. Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.
Aloj L; Aurilio M; Rinaldi V; D'ambrosio L; Tesauro D; Peitl PK; Maina T; Mansi R; von Guggenberg E; Joosten L; Sosabowski JK; Breeman WA; De Blois E; Koelewijn S; Melis M; Waser B; Beetschen K; Reubi JC; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1417-25. PubMed ID: 21523391
[TBL] [Abstract][Full Text] [Related]
2. Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides.
Laverman P; Joosten L; Eek A; Roosenburg S; Peitl PK; Maina T; Mäcke H; Aloj L; von Guggenberg E; Sosabowski JK; de Jong M; Reubi JC; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1410-6. PubMed ID: 21461732
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.
Ocak M; Helbok A; Rangger C; Peitl PK; Nock BA; Morelli G; Eek A; Sosabowski JK; Breeman WA; Reubi JC; Decristoforo C
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1426-35. PubMed ID: 21528387
[TBL] [Abstract][Full Text] [Related]
4. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
6. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
[TBL] [Abstract][Full Text] [Related]
7. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.
Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729
[TBL] [Abstract][Full Text] [Related]
8. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
Sosabowski JK; Matzow T; Foster JM; Finucane C; Ellison D; Watson SA; Mather SJ
J Nucl Med; 2009 Dec; 50(12):2082-9. PubMed ID: 19910426
[TBL] [Abstract][Full Text] [Related]
9. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
11. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
12. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of gastrin derivatives labelled with 111In: radiolabelling, affinity profile and pharmacokinetics in rats.
Melicharova L; Laznickova A; Laznicek M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):544-51. PubMed ID: 24108197
[TBL] [Abstract][Full Text] [Related]
15. In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands.
Kaloudi A; Nock BA; Lymperis E; Sallegger W; Krenning EP; de Jong M; Maina T
Nucl Med Biol; 2015 Nov; 42(11):824-32. PubMed ID: 26300210
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
18. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.
Kolenc-Peitl P; Mansi R; Tamma M; Gmeiner-Stopar T; Sollner-Dolenc M; Waser B; Baum RP; Reubi JC; Maecke HR
J Med Chem; 2011 Apr; 54(8):2602-9. PubMed ID: 21456601
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.
von Guggenberg E; Rangger C; Sosabowski J; Laverman P; Reubi JC; Virgolini IJ; Decristoforo C
Mol Imaging Biol; 2012 Jun; 14(3):366-75. PubMed ID: 21732165
[TBL] [Abstract][Full Text] [Related]
20. Radiolabelled CCK
Novak D; Tomašič T; Krošelj M; Javornik U; Plavec J; Anderluh M; Kolenc Peitl P
ChemMedChem; 2021 Jan; 16(1):155-163. PubMed ID: 32643833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
